

NCIC CLINICAL TRIALS GROUP

SYMPTOM CONTROL

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON
ROOM: ROSSETTI

MAY 1, 2011 – 8:00 AM – 12:00 PM (OPEN)

CHAIR: REBECCA WONG

1. To review the results of recent clinical trials in controlling symptoms of patients with cancer and to enhance understandings of the trials' results with respect to intervention adoption.
2. To review aspects of standard care of patients with bone metastases and neuropathic pain specifically as these practices relate to new NCIC CTG priority initiatives.
3. To explore understandings of distress in patients with cancer and consider interventions that might alleviate this symptom.
4. To review the potential implications of companion / correlative objectives of NCIC CTG symptom control trials including translational research and QoL.

800	Welcome and Introductions	R. Wong
805 – 845	Current Studies <ul style="list-style-type: none"> • SC.20 and SC.20U • SC.22 • SC.23 • CO.21 • ES.2 	J. Wu B. Gagnon K. Dennis / C. De Angelis C. Booth R. Wong
	Trial Proposal	
845 – 920	Stereotactic body radiotherapy for high risk spine metastases	A.Saghal
920 – 955	Dose fractionation study for neuropathic pain	K. Dennis / C. De Angelis
955 – 1015	Coffee Break	
1015 – 1050	Olanzapine and chemotherapy induced nausea	D. Warr
1050 - 1125	Psychotherapeutic intervention for depression/distress in metastatic cancer	G. Rodin
1125 – 1150	NCI	
	NCI QoL & Symptom Control Committee update NCI Symptom control trials	M. Brundage R. Wong
1150 - 12	Other Business	All
12	Meeting Adjourned	
12 – 130	Executive Committee meeting to follow (closed)	